Jane Street’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.45M | Buy |
210,243
+160,602
| +324% | +$1.24M | ﹤0.01% | 5707 |
|
|
2025
Q4 | $438K | Sell |
49,641
-109,429
| -69% | -$602K | ﹤0.01% | 8004 |
|
|
2025
Q3 | $794K | Buy |
159,070
+79,963
| +101% | +$370K | ﹤0.01% | 6822 |
|
|
2025
Q2 | $373K | Buy |
79,107
+17,833
| +29% | +$78K | ﹤0.01% | 7453 |
|
|
2025
Q1 | $281K | Buy |
61,274
+37,661
| +159% | +$176K | ﹤0.01% | 7920 |
|
|
2024
Q4 | $113K | Sell |
23,613
-41,678
| -64% | -$200K | ﹤0.01% | 8717 |
|
|
2024
Q3 | $306K | Sell |
65,291
-45,605
| -41% | -$244K | ﹤0.01% | 8007 |
|
|
2024
Q2 | $627K | Buy |
110,896
+48,992
| +79% | +$253K | ﹤0.01% | 6655 |
|
|
2024
Q1 | $254K | Sell |
61,904
-31,311
| -34% | -$125K | ﹤0.01% | 7809 |
|
|
2023
Q4 | $393K | Sell |
93,215
-149,541
| -62% | -$603K | ﹤0.01% | 7186 |
|
|
2023
Q3 | $1.05M | Buy |
242,756
+199,963
| +467% | +$1.11M | ﹤0.01% | 5110 |
|
|
2023
Q2 | $282K | Buy |
+42,793
| New | +$274K | ﹤0.01% | 7227 |
|
|
2021
Q4 | – | Sell |
-10,743
| Closed | -$187K | – | 10856 |
|
|
2021
Q3 | $184K | Buy |
10,743
+408
| +4% | +$7.15K | ﹤0.01% | 8916 |
|
|
2021
Q2 | $222K | Sell |
10,335
-7,422
| -42% | -$133K | ﹤0.01% | 8658 |
|
|
2021
Q1 | $267K | Sell |
17,757
-2,549
| -13% | -$41.3K | ﹤0.01% | 7862 |
|
|
2020
Q4 | $267K | Sell |
20,306
-13,353
| -40% | -$161K | ﹤0.01% | 6569 |
|
|
2020
Q3 | $326K | Buy |
+33,659
| New | +$360K | ﹤0.01% | 5765 |
|
|
2020
Q1 | – | Sell |
-23,414
| Closed | -$384K | – | 6046 |
|
|
2019
Q4 | $384K | Buy |
+23,414
| New | +$354K | ﹤0.01% | 4001 |
|
|
2018
Q2 | – | Sell |
-15,282
| Closed | -$258K | – | 5670 |
|
|
2018
Q1 | $258K | Buy |
+15,282
| New | +$256K | ﹤0.01% | 4197 |
|
|
2017
Q2 | – | Sell |
-22,187
| Closed | -$311K | – | 4921 |
|
|
2017
Q1 | $311K | Sell |
22,187
-3,960
| -15% | -$56.4K | ﹤0.01% | 3398 |
|
|
2016
Q4 | $417K | Sell |
26,147
-4,048
| -13% | -$65.1K | ﹤0.01% | 3033 |
|
|
2016
Q3 | $503K | Buy |
30,195
+12,322
| +69% | +$166K | ﹤0.01% | 2769 |
|
|
2016
Q2 | $200K | Buy |
+17,873
| New | +$173K | ﹤0.01% | 3753 |
|
|
2015
Q1 | – | Sell |
-15,454
| Closed | -$221K | – | 3526 |
|
|
2014
Q4 | $221K | Sell |
15,454
-17,709
| -53% | -$210K | ﹤0.01% | 2134 |
|
|
2014
Q3 | $344K | Buy |
+33,163
| New | +$435K | ﹤0.01% | 1774 |
|
|
2014
Q2 | – | Sell |
-16,144
| Closed | -$262K | – | 3165 |
|
|
2014
Q1 | $262K | Buy |
+16,144
| New | +$230K | ﹤0.01% | 2108 |
|
Other funds holding VNDA
ACM
VCM
Jane Street's VNDA Position: Q1 2026 in Review
Jane Street increased its Vanda Pharmaceuticals (VNDA) stake by 324% in Q1 2026, buying an estimated $1.24M and bringing the position to 210,243 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #5707.
Jane Street first reported a position in VNDA in Q1 2014 and has held it in 26 quarters since. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.
- Jane Street held 210,243 shares of Vanda Pharmaceuticals worth $1.45M as of Q1 2026.
- Jane Street bought 160,602 Vanda Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
- Vanda Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5707 holding.
- Jane Street first reported a position in Vanda Pharmaceuticals in Q1 2014 and has held it in 26 quarters since.
- 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.